Clinical Trials Logo

Clinical Trial Summary

Assisted reproductive technology (ART), especially controlled ovarian stimulation (COS), significantly increased clinical pregnancy rates among infertile patients. However, about 9% to 24% of patients had poor ovarian response to gonadotropins (GNS) stimulation, which was called poor ovarian response (POR). In recent years, the diagnosis and treatment of patients with low fertility is the challenge for reproductive medicine. To better demonstrate the effectiveness of various interventions and distinguish the different subgroups of patients, 2016 POSEIDON (Patient-Oriented Strategies Encompassing Individualized Oocyte Number) standard changed low reaction into low prognosis of patient-oriented individual strategies to obtain eggs. For patients in group 3 and group 4 classified by POSEIDON, ovarian reserve function decline, follicular development desynchrony and low numbers of oocytes obtained lead to poor prognosis. In 2020, the prognosis based on Delphi method of assisted reproductive technology to treat low crowd diagnosis expert opinion in China recommended to give these patients conventional cosine solutions such as antagonist. In the first cycle, follicle stimulating hormone (FSH) starting dose of 225 ~ 300 iu is suggested to achieve plenty of ovarian stimulation for standards and maximize the benefits of superovulation. Because of the particularity of luteal support in the antagonist regimen, it is of great clinical significance to explore the trigger mode and combination mode of luteal support in the antagonist regimen for patients with poor prognosis.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04717752
Study type Interventional
Source Nanjing University
Contact
Status Recruiting
Phase N/A
Start date January 20, 2021
Completion date December 31, 2021

See also
  Status Clinical Trial Phase
Completed NCT03433768 - Androgen Receptor mRNA Expression is Positively Associated With Live Birth in Women Undergoing IVF Independently of the Type of Ovarian Response N/A
Recruiting NCT05601193 - Ovarian PRP Injection in Women With POR N/A
Suspended NCT03021915 - Single Center, Prospective Controlled Pilot Study of the OvaPrime Procedure N/A
Completed NCT04013984 - Acupuncture for Treatment of Patients With Poor Ovarian Response N/A
Completed NCT03447184 - Long-term Endogenous Androgen Priming in Bologna Criteria Poor Responder Patients - A Pilot Study
Completed NCT01816321 - Corifollitropin Alfa Followed by Menotropin for Poor Ovarian Responders Trial Phase 3
Recruiting NCT04310293 - Novel Therapy for Poor Responders Management N/A
Completed NCT05703308 - Menstrual Blood Stem Cells in Poor Ovarian Responders Phase 3
Terminated NCT00878124 - How Dose Coenzyme Q10 Supplementation During Infertility Treatment Effects Pregnancy Outcome N/A
Completed NCT01732094 - Corifollitropin Alfa Followed by hpHMG in a Long GnRH Agonist Protocol for the Treatment of Poor Ovarian Responders Phase 2
Completed NCT01732068 - Treatment of Poor Ovarian Responders With Corifollitropin Alfa Followed by hpHMG in a Short GnRH Agonist Protocol Phase 2
Recruiting NCT06089395 - The Effect of Jiajian Guishen Granules on the Modulation of Ovarian Function in Patients With Poor Ovarian Response(POR) Early Phase 1
Recruiting NCT04024722 - Improving in Vitro Fertilization in Women With Poor Ovarian Response N/A
Completed NCT03994614 - the Effect of Transcutaneous Electrical Acupoint Stimulation on the Quality of Oocyte on Poor Ovarian Response(POR) N/A
Recruiting NCT03830697 - A Trial Study on Acupuncture Treatment of Poor Ovarian Response N/A
Recruiting NCT02801591 - Effect of Recombinant Human Growth Hormone Injection on the Clinical Outcome of POR in Patients Undergoing IVF/ET N/A
Recruiting NCT04273256 - Myo-inositol for the Management of Poor Ovarian Responders: A Prospective Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT02993588 - Impact of Melatonin on IVF/ICSI Outcomes in Prospective Poor Responders Phase 2/Phase 3
Recruiting NCT02418572 - Testosterone TRANSdermal Gel for Poor Ovarian Responders Trial Phase 3